ERCC1 Cys8092Ala and XRCC1 Arg399Gln polymorphisms predict progression-free survival after curative radiotherapy for nasopharyngeal carcinoma

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Jin, Hekun ^a   Xie, Xiaoxue ^b   Wang, Hui ^b   Hu, Jun ^b   Liu, Feng ^b   Liu, Zhigang ^b   Zhou, Jumei ^b   Zhang, Yingying ^a   Xi, Xuping ^b   Hu, Bingqiang ^b   Liao, Yuping ^a   Tang, Jingtian ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; CISPLATIN; CYSTEINE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTAMINE; PROTEIN KINASE B; PROTEIN P53; XRCC1 PROTEIN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 1;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALLELE; AMINO ACID SEQUENCE; ARTICLE; BIOPSY TECHNIQUE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; GENOTYPE; HETEROZYGOTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE; AMINO ACID SUBSTITUTION; DNA SEQUENCE; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; RISK FACTOR; YOUNG ADULT;

ADULT; AGED; ALLELES; AMINO ACID SUBSTITUTION; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; POLYMORPHISM, GENETIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RETROSPECTIVE STUDIES; RISK FACTORS; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84904264439     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101256     Document Type: Article

References (46)

1. Monaco R, Rosal R, Dolan MA, Pincus MR, Brandt-Rauf PW (2007) Conformational effects of a common codon 399 polymorphism on the BRCT1 domain of the XRCC1 protein. Protein J 26: 541-546. (Pubitemid 350060770)
2. Zipprich J, Terry MB, Brandt-Rauf P, Freyer GA, Liao Y, et al. (2010) XRCC1 polymorphisms and breast cancer risk from the New York site of the breast cancer family registry: a family-based case-control study. J Carcinog 9: 4.
3. Hu JJ, Smith TR, Miller MS, Lohman K, Case LD (2002) Genetic regulation of ionizing radiation sensitivity and breast cancer risk. Environ Mol Mutagen 39:208-215. (Pubitemid 34260495)
4. Hu JJ, Smith TR, Miller MS, Mohrenweiser HW, Golden A, et al. (2001) Amino acid substitution variants of APE1 and XRCC1 genes associated with ionizing radiation sensitivity. Carcinogenesis 22: 917-922. (Pubitemid 32514958)
5. Angelini S, Kumar R, Carbone F, Maffei F, Forti GC, et al. (2005) Micronuclei in humans induced by exposure to low level of ionizing radiation: influence of polymorphisms in DNA repair genes. Mutat Res 570: 105-117. (Pubitemid 40179273)
6. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA (1999) XRCC1 polymorphisms: Effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59: 2557-2561. (Pubitemid 29269097)
7. Wilson MD, Ruttan CC, Koop BF, Glickman BW (2001) ERCC1: a comparative genomic perspective. Environ Mol Mutagen 38: 209-215.
8. Sijbers AM, de Laat WL, Ariza RR, Biggerstaff M, Wei YF, et al. (1996) Xeroderma pigmentosum group F caused by a defect in a structurespecific DNA repair endonuclease. Cell 86: 811-822. (Pubitemid 26303449)
9. Shen MR, Jones IM, Mohrenweiser H (1998) Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58: 604-608. (Pubitemid 28099464)
10. McGurk CJ, Cummings M, Koberle B, Hartley JA, Oliver RT, et al. (2006) Regulation of DNA repair gene expression in human cancer cell lines. J Cell Biochem 97: 1121-1136.
11. Yang M, Kim WH, Choi Y, Lee SH, Kim KR, et al. (2006) Effects of ERCC1 expression in peripheral blood on the risk of head and neck cancer. Eur J Cancer Prev 15: 269-273. (Pubitemid 43791775)
12. Chen P, Wiencke J, Aldape K, Kesler-Diaz A, Miike R, et al. (2000) Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev 9: 843-847. (Pubitemid 30660059)
13. Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yukiue H, et al. (2011) Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res 168: 206-212.
14. Takenaka T, Yano T, Kiyohara C, Miura N, Kouso H, et al. (2010) Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients. Lung Cancer 67: 101-107.
15. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, et al. (2004) Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 10: 4939-4943. (Pubitemid 39099767)
16. Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10: 54-61.
17. Erčulj N, Kovač V, Hmeljak J, Franko A, Dodič-Fikfak M, et al. (2012) The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesothelioma. Ann Oncol 23: 961-967.
18. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, et al. (2006) DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 24: 4333-4339. (Pubitemid 46630792)
19. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, et al. (2009) DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 10: 118-123.
20. Wu X, Lu C, Ye Y, Chang J, Yang H, et al. (2008) Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 18: 955-965.
21. Wang Y, Chen J, Li X, He Y, Hu B, et al. (2011) Genetic polymorphisms of ERCC1 and their effects on the efficacy of cisplatin-based chemotherapy in advanced esophageal carcinoma. Oncol Rep 25: 1047-1052.
22. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, et al. (2011) No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a metaanalysis. Lung Cancer 72: 370-377.
23. Park SY, Hong YC, Kim JH, Kwak SM, Cho JH, et al. (2006) Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol 23: 489-498.
24. Hara A, Okayasu I (2004) Cyclooxygenase-2 and inducible nitric oxide synthase expression in human astrocytic gliomas: correlation with angiogenesis and prognostic significance. Acta Neuropathol 2004, 108:43-48. (Pubitemid 38961072)
25. Tuimala J, Szekely G, Wikman H, Järventaus H, Hirvonen A, et al. (2004) Genetic polymorphisms of DNA repair and xenobiotic-metabolizing enzymes: effects on levels of sister chromatid exchanges and chromosomal aberrations. Mutat Res 554: 319-333. (Pubitemid 39140839)
26. Kiuru A, Lindholm C, Heilimo I, Ceppi M, Koivistoinen A, et al. (2005) Influence of DNA repair gene polymorphisms on the yield of chromosomal aberrations. Environ Mol Mutagen 46: 198-205. (Pubitemid 41642312)
27. Pastorelli R, Cerri A, Mezzetti M, Consonni E, Airoldi L (2002) Effect of DNA repair gene polymorphisms on BPDE-DNA adducts in human lymphocytes. Int J Cancer 100: 9-13. (Pubitemid 34602058)
28. Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, et al. (2000) Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92: 1764-1772.
29. Ito H, Matsuo K, Hamajima N, Mitsudomi T, Sugiura T, et al. (2004) Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis 25: 1395-1401. (Pubitemid 39162705)
30. Zhou W, Liu G, Miller DP, Thurston SW, Xu LL, et al. (2003) Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 12: 359-365. (Pubitemid 36427997)
31. Wei Q, Eicher SA, Guan Y, Cheng L, Xu J, et al. (1998) Reduced expression of hMLH1 and hGTBP: a risk factor for head and neck cancer. Cancer Epidemiol Biomarkers Prev 7: 309-314. (Pubitemid 28354142)
32. Abdel-Rahman SZ, El-Zein RA (2000) The Gln399 polymorphism in the DNA repair gene XRCC1 modulates the genotoxic response induced in human lymphocytes by the tobacco-specific nitrosamine NNK. Cancer Lett 159: 63-71.
33. Lei YC, Hwang SJ, Chang CC, Kuo HW, Luo JC, et al. (2002) Effects on sister chromatid exchange frequency of polymorphisms in DNA repair gene XRCC1 in smokers. Mutat Res 519: 93-101.
34. Salles B, Sattler U, Bozzato C, Calsou P (1999) Repair of oxidative DNA damage in vitro: a tool for screening antioxidative compounds. Food Chem Toxicol 37: 1009-14. (Pubitemid 29481805)
35. Marintchev A, Robertson A, Dimitriadis EK, Prasad R, Wilson SH, et al. (2000) Domain specific interaction in the XRCC1-DNA polymerase complex. Nucleic Acids Res 28: 2049-2059. (Pubitemid 30255525)
36. Yang ZH, Dai Q, Kong XL, Yang WL, Zhang L (2009) Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma. Mol Carcinog 48: 196-201.
37. Chen C, Wang F, Wang Z, Li C, Luo H, et al. (2013) Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol 72: 315-322.
38. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, et al. (2004) The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 24: 5776-5787. (Pubitemid 38787963)
39. McMillan TJ, Steel GG (2002) DNA damage and cell killing. In: Steel GG, editor. Basic clinical radiobiology. 3rd ed. London: Hodder Arnold. pp. 71-83.
40. Levine AJ (1992) The p53 tumor suppressor gene and product. Cancer Surv 12: 59-79.
41. Maity A, Kao GD, Muschel RJ, McKenna WG (1997) Potential moleculer targets for manipulating the radiation response. Int J Radiat Oncol Biol Phys 37: 639-653. (Pubitemid 27175320)
42. Masuda M, Shinokuma A, Hirakawa N, Nakashima T, Komiyama S (1998) Expression of bcl-2, p53, and Ki-67 and outcome of patients with primary nasopharyngeal carcinomas following DNA-damaging treatment. Head Neck 20: 640-644. (Pubitemid 28405808)
43. Ma BB, Poon TC, To KF, Zee B, Mo FK, et al. (2003) Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma-a prospective study. Head Neck 25: 864-872. (Pubitemid 37139899)
44. Wang LF, Chai CY, Kuo WR, Tai CF, Lee KW, et al. (2006) The prognostic value of proliferating cell nuclear antigen (PCNA) and p53 protein expression in patients with advanced nasopharyngeal carcinoma. Acta Otolaryngol 126: 769-774.
45. Yip WK, Leong VC, Abdullah MA, Yusoff S, Seow HF (2008) Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol Rep 19: 319-328. (Pubitemid 351176090)
46. Ogawara Y, Kishishita S, Obata T, Isazawa Y, Suzuki T, et al. (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J Biol Chem 277: 21843-21850. (Pubitemid 34952337)